News & Updates

Low-dose polypill: Another step forward in hypertension management?
Low-dose polypill: Another step forward in hypertension management?
12 Dec 2022 byRoshini Claire Anthony

A polypill comprising ultra-low doses of four antihypertensive drugs shows promise in reducing blood pressure (BP) levels compared with standard monotherapy, according to a small study presented at AHA 2022.

Low-dose polypill: Another step forward in hypertension management?
12 Dec 2022
CV benefits of dapagliflozin evident regardless of baseline kidney function
CV benefits of dapagliflozin evident regardless of baseline kidney function
11 Dec 2022 byRoshini Claire Anthony

The cardiovascular (CV) benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is evident regardless of baseline kidney function, according to an analysis of the DELIVER* trial presented at Kidney Week 2022.

CV benefits of dapagliflozin evident regardless of baseline kidney function
11 Dec 2022
Add-on radiation therapy poses higher cardiovascular risk in stage III NSCLC
Add-on radiation therapy poses higher cardiovascular risk in stage III NSCLC
09 Dec 2022
Diabetes and COVID-19: What have we learned so far?
Diabetes and COVID-19: What have we learned so far?
09 Dec 2022 byKanas Chan

Evidence for excess risk and increased burden of new-onset diabetes among COVID-19 survivors is robust, and most antihyperglycaemic drugs can be used safely during acute COVID-19, with some drugs potentially offering protection against serious complications, according to data presented at 5th EDM HK.

Diabetes and COVID-19: What have we learned so far?
09 Dec 2022